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Is a compact preﬁlled auto-disable injection
system (cPAD) cost effective for pentavalent
vaccine?
C. Nogier ∗, P. Hanlon, K. Wiedenmayer, N. Maire
Swiss Tropical and Public Health Institute, Basel,
Switzerland
Background: Thepentavalent combinationvaccine is theWHO-
recommended form of the DTP-HepB-Hib vaccine. It is available
in single dose vial (SDV), multi-dose vials (MDV) and soon in a
compact preﬁlled auto-disable injection system (cPAD). A costing
model was developed and used in three countries to perform a
Cost-Effectiveness Analysis (CEA) of these three presentations.
Methods & Materials: The model included the costs of vaccine,
safe injection equipment, storage, transport, distribution, vaccine
administration by health staff, waste management, start-up activi-
ties, coverage andwastage rates. The outcomewas the incremental
cost/savingper fully immunizedchild (FIC) for a switch to cPAD. The
model was used in Peru, Ghana and Cambodia. Field visits to health
facilities, interviews with key informants from immunization ser-
vices and regulatory affairs were conducted.
Results: Based on vaccine price trends estimated for the year
2016, cPAD would be more cost-effective in Ghana compared to
the current presentation (MDV-10) and in Peru (SDV). In Cambodia,
cPAD would be less cost effective (SDV).
The most signiﬁcant driver of the cost per FIC is the cost of the
vaccine (including compensation for vaccine wastage) in any pre-
sentation: accounting for 85% of total cost in Peru and over 97% in
the two other countries. The dominance of the vaccine price per
dose and to a lesser extent the wastage rates and cost of safe injec-
tion equipment as drivers of the incremental cost per FIC show
the potential to simplify future analyses. Programmatic contexts
and perceptions of stakeholders inﬂuence the decision to introduce
new vaccine presentations. Other factors include the potential for
improved safetywith cPAD, planned introduction of other vaccines
and environmental issues relating to reduced waste generation.
Conclusion: Based on vaccine price estimated for the year 2016,
the cPAD could be the most cost-effective presentation in many
countries. For decision making and policy dialogue other factors
(injection safety, programmatic aspects, etc.) may be important
when considering shifting to a new vaccine presentation such as
cPAD.
Conﬂict of interest: Crucell funded the study.
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Incremental cost per FIC
USD (%)
0.32 (+3.76%) −0.58 (-6.41%) −0.90 (-7.20%)
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Clinical development of a recombinant live
attenuated tetravalent dengue vaccine
J. Osorio
Takeda vaccines, Madison, USA
Background: Takeda is developinga tetravalent, live attenuated
dengue vaccine (LADV) consisting of a molecularly characterized,
attenuatedDENV-2 strain and three chimeras inwhich the prMand
E genes of the attenuated DENV-2 were substituted with those of
DENV- 1, -3 or -4 viruses.
Methods & Materials: Takeda is conducting Phase 1 and 2 clin-
ical trials for the LADV
Results: The results of our Phase 1 and 2 clinical trials in healthy
subjects support the safety and immunogenicity of the tetravalent
vaccine. Administration of LADV was generally well-tolerated with
mostly mild and transient local or systemic reactions. There were
no related serious or severe adverse events (AEs), and no discontin-
uations due to vaccine-related AEs. The LADV induced neutralizing
antibody responses to all four dengue viruses after one or two
administrations.
Conclusion: These studies highlight the safety and immuno-
genicity of the tetravalent LADV vaccine in children and adults in
dengue endemic countries. Based on our results from Phase 1 and
2 studies, the LADV warrants further evaluation in Phase 3 efﬁcacy
studies in children and adults in dengue-endemic countries.
http://dx.doi.org/10.1016/j.ijid.2014.03.1324
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A large single-center retrospective analysis of
neutralizing antibodies after intradermal
pre-exposure rabies vaccination
P. Geeraerts1, A. Collee1, P. Soentjens2,∗
1 Division Health, Well Being, Brussels, Belgium
2 Centre for Infectious Diseases, Brussels, Belgium
Background: Soldiers in the Belgian Defence are intradermally
vaccinated for rabies pre-deployment since 2008 by a four injec-
tion schedule (day 0,7, 28, 365). Neutralizing antibody titers against
rabieswere tested7days after booster vaccination. Serology results
of subjects, vaccinated between the 1st of april 2008 and the 31st
of june 2013, were evaluated. A titer of the Rapid Fluorescent Focus
Inhibition Test (RFFIT) ≥ 0,5 IU/ml is considered to be boostable. A
titer >3,0 IU/ml is considered to give sufﬁcient protection and>10
IU/ml a long-lasting immunity.
